The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Current and novel treatment approaches for first-line EGFR-m NSCLC
David Lee, MBBS, University of Malaya, Kuala Lumpur, Malaysia, comments on treatment strategies for patients with EGFR-mutated non-small cell lung cancer (NSCLC) in the first line setting. Single agent EGFR tyrosine kinase inhibitors (TKIs) are the standard of care, but access to newer generations of TKIs remain an issue in middle/lower income countries. The approval of the recently approved bispecific antibody amivantamab and addition of chemotherapy assessed in the FLAURA2 trial (NCT04035486) both represent novel strategies as well. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
